Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Small Cell
  • Lung Neoplasms
  • Proto-Oncogene Proteins c-bcl-2
  • Thionucleotides

abstract

  • The combination of G3139, carboplatin, and etoposide is well tolerated and results in an encouraging response rate and time to progression in patients with extensive stage SCLC.

publication date

  • December 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2004.10.148

PubMed ID

  • 15020613

Additional Document Info

start page

  • 1110

end page

  • 7

volume

  • 22

number

  • 6